Nabriva Therapeutics (Nabriva Therapeutics) Debt-to-Asset

: 0.05 (As of Jun. 2023)

View and export this data going back to 2017. Start your Free Trial

Nabriva Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.20 Mil. Nabriva Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.34 Mil. Nabriva Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2023 was $10.58 Mil. Nabriva Therapeutics's debt to asset for the quarter that ended in Jun. 2023 was 0.05.

Nabriva Therapeutics Debt-to-Asset Historical Data

The historical data trend for Nabriva Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nabriva Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Asset

0.22

0.37

0.13

0.10

0.16

Nabriva Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Debt-to-Asset																0.13	0.13	0.16	0.02	0.05

Competitive Comparison

For the Biotechnology subindustry, Nabriva Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nabriva Therapeutics Debt-to-Asset Distribution

For the Biotechnology industry and Healthcare sector, Nabriva Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Nabriva Therapeutics's Debt-to-Asset falls into.

Nabriva Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Nabriva Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(4.833	+	0.388)	/	31.765
	=	0.16

Nabriva Therapeutics's Debt-to-Asset for the quarter that ended in Jun. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.196	+	0.344)	/	10.578
	=	0.05

Nabriva Therapeutics (OTCPK:NBRVF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Nabriva Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Nabriva Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Nabriva Therapeutics (Nabriva Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nabriva Therapeutics PLC (OTCPK:NBRVF) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Alexandra House, Office 225/227, The Sweepstakes, Dublin, IRL, 4

Website

https://www.nabriva.com

Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.

Executives

Hogan H Michael Iii	officer: Chief Executive Officer	C/O 3D SYSTEMS, 26081 AVENUE HALL, VALENCIA CA 91355
David Maggio	officer: Chief Financial Officer	15950 N. DALLAS PARKWAY, SUITE 600, DALLAS TX 75248
Mark Corrigan	director
Broom Colin Md	officer: Chief Executive Officer	119 FRINGETREE DRIVE, WEST CHESTER PA 19380
Stephen W Webster	director	C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, SAN DIEGO CA 07302
Daniel D Burgess	director	C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121
Carrie L. Bourdow	officer: Director	C/O TREVENA, INC., 1018 WEST 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Rowland Charles A Jr	director	3338 LANCASHIRE RD, FURLONG PA 18925
Theodore R Schroeder	officer: Chief Executive Officer	12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
J. Christopher Naftzger	officer: General Counsel and Corp Sec	633 LOWTHER ROAD, LEWISBERRY PA 17339
Christine J. Guico-pabia	officer: Chief Medical Officer	C/O NABRIVA THERAPEUTICS PLC, 414 COMMERCE DRIVE, SUITE 120, FORT WASHINGTON PA 19034
Lisa Dalton	director	3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Daniel Dolan	officer: Chief Financial Officer	C/O NABRIVA THERAPEUTICS PLC, 1000 CONTINENTAL DRIVE, SUITE 600, KING OF PRUSSIA PA 19406
Francesco Maria Lavino	officer: Chief Commercial Officer	1000 CONTINENTAL DRIVE, SUITE 600, KING OF PRUSSIA PA 19406
Robert Crotty	officer: General Counsel & Corp Sec.	1301 2ND AVE, SEATTLE WA 98101